AZNAstraZenecaSigning up patients
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,330 (planned)
- Started
- Sep 15, 2026
- Main results expected
- May 30, 2031
- Fully finished
- May 27, 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Radiographic progression-free survival (rPFS)
Measured over: Up to approximately 56 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07711002 · record last updated 2026-10-15 · checked 2026-11-09 15:47 UTC